Category: Biotechnology
Global Biotechnology
-
Digestive Enzyme Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Animal Source, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$817.7 Million by the end of ... Read More
-
Liquid Handling Systems
... at a CAGR of 4.6% over the analysis period 2024-2030. Automated, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$2.9 Billion by the end of the ... Read More
-
Mass Spectrometry
... CAGR of 3.7% over the analysis period 2024-2030. Hybrid, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$3.7 Billion by the end of the analysis period. ... Read More
-
Proteases
... 5.5% over the analysis period 2024-2030. Microbes, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in ... Read More
-
Biopharmaceutical Logistics
... CAGR of 4.8% over the analysis period 2024-2030. Cold Chain Logistics, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$37.9 Billion by the end of the ... Read More
-
qPCR Reagents
... CAGR of 7.4% over the analysis period 2024-2030. Dye-Based qPCR Reagents, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$2.5 Billion by the end of the ... Read More
-
Single-Cell Analysis
... CAGR of 18.6% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 20.5% CAGR and reach US$11.1 Billion by the end of the analysis period. ... Read More
-
Stem Cell Assays
... at a CAGR of 17.9% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$6.1 Billion by the end of the ... Read More
-
Life Science Instrumentation
... at a CAGR of 4.6% over the analysis period 2024-2030. Spectroscopy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$24.4 Billion by the end of the ... Read More
-
Microarray Analysis
... CAGR of 6.0% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$4.6 Billion by the end of the analysis period. ... Read More
-
Polymerase Chain Reaction
... at a CAGR of 5.0% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.4 Billion by the end of the ... Read More
-
Viral Inactivation
... CAGR of 11.6% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 11.5% CAGR and reach US$865.8 Million by the end of the ... Read More
-
Bread Improvers
... CAGR of 4.6% over the analysis period 2024-2030. Powder Form, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.6 Billion by the end of the analysis ... Read More
-
Cell Viability Assays
... at a CAGR of 7.1% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$5.3 Billion by the end of the ... Read More
-
Silage Additives
... CAGR of 4.8% over the analysis period 2024-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$1.5 Billion by the end of the analysis period. ... Read More
-
Chiral Chemicals
... CAGR of 6.2% over the analysis period 2024-2030. Traditional Separation Method, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$50.8 Billion by the end of the ... Read More
-
Gel Electrophoresis
... CAGR of 5.3% over the analysis period 2024-2030. Laboratory Research End-Use, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Gel Permeation Chromatography Systems
... 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Pharma & Biotech Companies End-Use, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$1.4 ... Read More
-
Glycomics / Glycobiology
... at a CAGR of 16.9% over the analysis period 2024-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the ... Read More
-
Humanized Mouse and Rat Model
... Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Humanized Rat Models, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$13.6 ... Read More
-
Exosomes
... 11.3% over the analysis period 2024-2030. Other Disease Indications, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$377.0 Million by the end of the analysis period. ... Read More
-
Fill Finish Manufacturing
... at a CAGR of 8.6% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Food Ultrasound
... CAGR of 4.5% over the analysis period 2024-2030. High-intensity Ultrasound, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$96.5 Million by the end of the analysis ... Read More
-
GMO Testing
... CAGR of 7.0% over the analysis period 2024-2030. Stacked Trait, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$2.6 Billion by the end of the analysis ... Read More
-
Human Liver Models
... at a CAGR of 9.3% over the analysis period 2024-2030. Liver Organoids, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$250.6 Million by the end of ... Read More
Research Assistance
